China Biologic Products, a blood products company, received a $4.6 billion takeover offer from a group of six investment firms. The proposal was priced at $120 per share, a 16% premium to the previous close. CBPO operates plasma-gathering facilities (China limits the number of such facilities) and offers 20 plasma-based products. The company is priced at about 30 times trailing earnings. One year ago, CITIC made a $3.9 billion offer for CBPO, which was topped by a syndicate led by a former CEO of the company. CBPO rejected both bids. Source: China Biotoday
